Showing results (91-100 of 170) with videos related to

Sort By:
Pageof 17
Sexual Medicine Reviews|February 4, 2018
Erectile Dysfunction and Subclinical Cardiovascular DiseaseMartin Miner, Sharon J Parish, Kevin L Billups, et al.
BJU International|April 26, 2014
Multicentre prospective crossover study of the 'prostatic urethral lift' for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasiaAnthony L Cantwell, William K Bogache, Steven F Richardson, et al.
BMC Urology|April 24, 2023
Study design of a phase 4, real-world study (COMPOSUR) to evaluate vibegron in patients with overactive bladderRoger R Dmochowski, Eric S Rovner, Michael J Kennelly, et al.
The Journal of Sexual Medicine|April 1, 2008
Vardenafil in men with stable statin therapy and dyslipidemiaMartin Miner, Larry Gilderman, James Bailen, et al.
Advances in Therapy|December 18, 2021
Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWURJeffrey Frankel, David Staskin, Susann Varano, et al.
The Journal of Urology|March 23, 2010
Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trialSender Herschorn, Lynn Stothers, Kevin Carlson, et al.
Atherosclerosis|February 18, 2014
Testosterone deficiency: a determinant of aortic stiffness in menCharalambos Vlachopoulos, Nikolaos Ioakeimidis, Martin Miner, et al.
Urology|June 18, 2013
A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladderSender Herschorn, Jack Barkin, David Castro-Diaz, et al.
Urology|January 27, 2009
Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: results from the BPH RegistryRaymond C Rosen, John T Wei, Stanley E Althof, et al.
Sexual Medicine Reviews|September 18, 2024
Newer formulations of oral testosterone undecanoate: development and liver side effectsIrwin Goldstein, Nachiappan Chidambaram, Adrian Dobs, et al.
Pageof 17